I'd certainly be happy to do that.
One of the reasons we're in this funny situation is that usually before a product becomes available for therapeutic use, it has to undergo rigorous research, clinical trials, and you have to demonstrate the evidence that the risk profile is acceptable.
Medicinal cannabis has come onto the scene through a series of legal challenges. Now it's available, and we have to look for the evidence to see what it might work for and what it might not work for. In many ways, the cart has gone in front of the horse here.
In terms of looking at its potential interactions with other drugs, I think that's such a critical question. There is a network in Canada called DSEN, the drug safety and effectiveness network, and they capitalize on the use of large-scale data through ISIS to see where there are drug-drug interactions. Certainly we benefited from that greatly when looking at the opioid guideline for understanding the interaction with benzodiazepines and other sedating medications as a real contraindication. The trial that Mr. Cohen referred to of Dravet syndrome, they did find, with a high dose of CBD, the potential for interaction with other seizure medications.
It's early days but we have to look into it seriously.